Impact of Mode of Anesthesia on Ischemia Modified Albumin in Patients With Traumatic Brain Injury

July 24, 2020 updated by: Abd-elrahman hassan abd -elaziz

Impact of Mode of Anesthesia on Ischemia Modified Albumin (Abiomarker of Oxidative Stress) and Outcome in Patients With Traumatic Brain Injury Undergoing Emergency Craniotomy

In the current study the investigators intend to evaluate the mode of anesthesia on ischemia modified albumin and outcome in patients with traumatic brain injury undergoing emergency craniotomy

Study Overview

Status

Unknown

Conditions

Detailed Description

After obtaining Institutional Ethical Committee approval and written informed consent from legally acceptable representative relatives, patients with traumatic brain injury, aged from 18- 60 years old, ASA from (I-III), GCS more than 8 undergoing emergency craniotomy surgery will be selected for this prospective randomized Study.

The anesthesia will be induced with 2mcg/kg fentanyl and 2 mg/kg propofol. Muscle relaxation will be achieved with 0.5 mg/kg atracurium.

Anesthesia will be maintained with:

  • Group I, isoflurane (mac<1) mixed with oxygen 40% and fentanyl 1mcg/kg hourly.
  • Group PD, propofol infusion(100-150mcg/kg/min) and dexmedetomedine 0.3mcg/kg /h.

Parameters will be assessed Preoperative period

  • Ischemia modified albumin level from venous sample.
  • Basal Systolic blood pressure, diastolic blood pressure. Mean arterial blood pressure, oxygen saturation, heart rate.
  • GCS. Intraoperative period
  • Systolic blood pressure, diastolic blood pressure. Mean arterial blood pressure, oxygen saturation, heart rate after intubation, 5,15,30,60,90min and after extubation.
  • Need for resuscitation with vasoactive drugs.
  • Brain relaxation score at dural opening and closure.
  • ICP
  • Intraoperative blood loss.
  • Amount of fluid and blood transfusion. Postoperative period
  • Ischemia modified albumin immediately postoperatively, after 6h and after 24 hours.
  • Type of surgery.
  • Duration of surgery.
  • Extubation time.
  • Recovery scores (Ramsay sedation score and modified Alderte score).
  • GCS immediately postoperatively, after 6h, after 24h and after 48 hours.
  • Total analgesic requirement during the first 24 hours.
  • Need for ICU admission.
  • Length of ICU stay.
  • Complications.
  • 28 day mortality.

Study Type

Observational

Enrollment (Anticipated)

54

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

patients with traumatic brain injury, aged from 18- 60 years old, ASA from (I-III), GCS more than 8 undergoing emergency craniotomy surgery

Description

Inclusion Criteria:

  1. Age 18-60 years old of both sex .
  2. Isolated traumatic brain injury undergoing emergency craniotomy.
  3. G.C.S more than 8.
  4. ASA grade (I-III).

Exclusion Criteria:

  1. Non traumatic brain injury.
  2. Poly trauma patient.
  3. Coagulation disorder.
  4. Drug( alcohol, opiods, tranquilizers) addiction.
  5. Liver and kidney dysfunction.
  6. Severe diseases such as severe hypertension, cardiovascular disease, malignant tumor, autoimmune disease, mental disorders.
  7. Diabetes mellitus with poor blood glucose control.
  8. Previous drug allergy.
  9. Currently lactating.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Inhalational
will receive inhalational anesthesia
Total intravenous
will receive total intravenous anesthesia with propofol infusion(100-150 mcg/kg/min) and dexmedetomedine 0.3mcg/kg/h.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
ischemia modified albumin
Time Frame: change from preoperative level of ischemia modified albumin at the first 24 hours postoperatively
Plasma Level of ischemia modified albumin
change from preoperative level of ischemia modified albumin at the first 24 hours postoperatively
Glascow Coma Scale
Time Frame: change from preoperative Glascow Coma Scale score at the first 24 hours postoperatively
Glascow Coma Scale records the state of a person's consciousness. it gives a person's score between 3 (indicating deep unconsciousness) and 15 (indicating fully consciousness)
change from preoperative Glascow Coma Scale score at the first 24 hours postoperatively

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Intraoperative blood pressure.
Time Frame: preoperatively, immediatly after intubation,after 5 minutes,afer 15 minutes,after 30 minutes,after 60 minutes,after 90 minutes and immediatly after extubation.
Intraoperative haemodynamics (Systolic blood pressure in millimeter mercury, diastolic blood pressure in millimeter mercury. Mean arterial blood pressure in millimeter mercury.
preoperatively, immediatly after intubation,after 5 minutes,afer 15 minutes,after 30 minutes,after 60 minutes,after 90 minutes and immediatly after extubation.
Intraoperative heart rate
Time Frame: preoperatively, immediatly after intubation,after 5 minutes,afer 15 minutes,after 30 minutes,after 60 minutes,after 90 minutes and immediatly after extubation.
Intraoperative heart rate per minute
preoperatively, immediatly after intubation,after 5 minutes,afer 15 minutes,after 30 minutes,after 60 minutes,after 90 minutes and immediatly after extubation.
I.C.U admission
Time Frame: up to 28 days
intensive care unit admission
up to 28 days
I.C.U stay.
Time Frame: up to 28 days
Length of stay in intensive care unit
up to 28 days
Incidence of any complication.
Time Frame: up to 28 days
Incidence of any complication (nausea, vomiting, convulsion and reopening).
up to 28 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Ahmed K Mohamed, professor, Minia University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

July 23, 2020

Primary Completion (Anticipated)

July 28, 2021

Study Completion (Anticipated)

October 30, 2021

Study Registration Dates

First Submitted

February 23, 2020

First Submitted That Met QC Criteria

July 24, 2020

First Posted (Actual)

July 28, 2020

Study Record Updates

Last Update Posted (Actual)

July 28, 2020

Last Update Submitted That Met QC Criteria

July 24, 2020

Last Verified

February 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Oxidative Stress

3
Subscribe